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Abstract
Background: Inflammatory bowel disease (IBD) is a chronic intestinal disorder that is associated with a limited number of
clinical biomarkers. In order to facilitate the diagnosis of IBD and assess its disease activity, we investigated the potential of
novel multivariate indexes using statistical modeling of plasma amino acid concentrations (aminogram).
Methodology and Principal Findings: We measured fasting plasma aminograms in 387 IBD patients (Crohn’s disease (CD),
n=165; ulcerative colitis (UC), n=222) and 210 healthy controls. Based on Fisher linear classifiers, multivariate indexes were
developed from the aminogram in discovery samples (CD, n=102; UC, n=102; age and sex-matched healthy controls,
n=102) and internally validated. The indexes were used to discriminate between CD or UC patients and healthy controls, as
well as between patients with active disease and those in remission. We assessed index performances using the area under
the curve of the receiver operating characteristic (ROC AUC). We observed significant alterations to the plasma aminogram,
including histidine and tryptophan. The multivariate indexes established from plasma aminograms were able to distinguish
CD or UC patients from healthy controls with ROC AUCs of 0.940 (95% confidence interval (CI): 0.898–0.983) and 0.894
(95%CI: 0.853–0.935), respectively in validation samples (CD, n=63; UC, n=120; healthy controls, n=108). In addition, other
indexes appeared to be a measure of disease activity. These indexes distinguished active CD or UC patients from each
remission patients with ROC AUCs of 0.894 (95%CI: 0.853–0.935) and 0.849 (95%CI: 0.770–0.928), and correlated with clinical
disease activity indexes for CD (rs=0.592, 95%CI: 0.385–0.742, p,0.001) or UC (rs=0.598, 95%CI: 0.452–0.713, p,0.001),
respectively.
Conclusions and Significance: In this study, we demonstrated that established multivariate indexes composed of plasma
amino acid profiles can serve as novel, non-invasive, objective biomarkers for the diagnosis and monitoring of IBD,
providing us with new insights into the pathophysiology of the disease.
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Introduction
Inflammatory bowel disease (IBD) is a chronic intestinal
disorder comprising two major types, Crohn’s disease (CD) and
ulcerative colitis (UC) [1,2]. Despite intensive research, the
etiology of IBD remains unknown, although it is considered to
be a multi-factorial disease determined by genetic backgrounds,
environmental factors and immunological disorders.
Importantly, the number of patients with IBD and colorectal
cancers in Asia has increased remarkably during the past decade.
One of the reasons for this change is thought to be the move
towards a more Westernized diet. Dietary habits are recognized to
be an important modifiable environmental factor influencing the
risk of these diseases. Most physicians believe in the role of diet
and nutritional metabolism in IBD pathogenesis, however, clinical
and basic research has not adequately addressed these issues.
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e31131The human body is a highly organized metabolic network of
systems that regulates individual homeostasis, but it is often
difficult to objectively assess. Analysis of the metabolomic
condition instead is therefore of use in determining health status,
as disturbances of metabolic homeostasis are known to be related
to the pathogenesis of metabolic syndromes, chronic inflammatory
disorders, and cancers. Post-genomic technologies, in particular
metabolomics, provide new opportunities to study metabolic
effects in relation to disease. Metabolomics is a rapidly evolving
field that comprehensively measures metabolites, ideally in a
biological fluid, and changes in metabolic profiles are a potential
source of biomarkers.
Overall, 20% of the human body is composed of amino acids
(AAs) and their metabolites, which play important roles as both
basic substrates and regulators in many metabolic pathways [3,4].
Specific abnormalities in plasma AA concentrations have been
reported in the context of various diseases, such as Fischer’s ratio
in fibrotic liver disease [5,6,7,8]. Plasma AA profiling is also a
potential screening tool for non-small cell lung carcinoma
(NSCLC) [9].
Previously, we demonstrated that aminograms and the
generation of a multivariate index using ‘‘AminoIndexTM technol-
ogy’’ (MIAI) have the potential for diagnostic use, disease activity
monitoring, and the assessment of pathophysiological conditions
[10]. Here, we introduced the concept of metabolomics to analyse
AA metabolism in IBD patients, and found that AA metabolism
was disturbed in IBD patients, particularly those with active
disease. AA profiles may reflect the nutritional condition of
individuals, disease activity, and differences in pathogenesis
between CD and UC. Finally, we established the novel clinical
parameter, the MIAI which discriminated between CD and UC,
and also reflected disease activity. We demonstrate for the first
time that disturbances of AA metabolism are related to the
pathophysiological state of IBD and that the MIAI is a novel, non-
invasive, diagnostic and monitoring marker for IBD.
Methods
Patients
IBD patients (n=387) were recruited between February 27,
2005, and March 7, 2008, at the Keio University Hospital, Tokyo,
Japan. Healthy controls (HCs; n=210) were recruited between
December 1, 2005, and April 1, 2006, from the Center for
Multiphasic Health Testing and Services, Mitsui Memorial
Hospital, Tokyo, Japan. Patients and HCs were divided into
discovery and validation sets. For the discovery screening, plasma
samples were obtained from CD patients (n=102), UC patients
(n=102) and age and sex-matched HCs (n=102). For the
validation test, plasma samples were obtained from CD patients
(n=63), UC patients (n=120) and HCs (n=108).
Patient and HC characteristics are shown in Table 1. For
continuous monitoring, IBD patients (n=22) were recruited
between May 30, 2005, and February 18, 2010, at Keio University
Hospital. This study was conducted in accordance with the
Declaration of Helsinki, and the protocol was approved by the
ethics committees of the Keio University School of Medicine and
the Mitsui Memorial Hospital. Signed informed consent forms
were obtained from all patients and all data were analyzed
anonymously throughout the study. The diagnosis of UC and CD
was based on established clinical, radiographic, endoscopic, and
histopathologic criteria. Patient characteristics were determined
from medical records, questionnaires, and interviews. Disease
activity was assessed by the Crohn’s disease activity index (CDAI)
[11] and the Lichtiger Clinical Activity Index (CAI) [12]. Active
disease was defined as CDAI$150 for patients with CD and
CAI$5 for patients with UC. Remission was defined as
CDAI,150 for patients with CD and CAI,5 for patients with
UC.
Plasma AA analysis
Plasma samples for AA analysis were obtained using EDTA as
an anticoagulant and stored at 280uC until analysis. Frozen
plasma samples were briefly thawed, mixed with 5-sulfosalicylic
acid (final concentration, 2.3%), then centrifuged for 10 min at
11,0006g at 4uC to remove precipitated proteins. Measurement
of AA concentrations was performed using an automatic AA
analyzer (L-8500; Hitachi High-Technologies Corporation, To-
kyo, Japan). Briefly, AAs separated by cation-exchange chroma-
tography were detected spectrophotometrically after a post-
column reaction with ninhydrin reagent. We confirmed that the
fasting plasma aminograms remained constant for individuals in
this protocol.
Statistical analysis
For comparisons between study groups, we used the Mann-
Whitney U test with Bonferroni correction. The Spearman
correlation was used to test associations of CDAI, CAI and serum
C-reactive protein (CRP) with the MIAI. These univariate
statistical analyses were performed using Prism software, version
5.0.1 (Graph Pad Software, San Diego, CA). Correlation
scatterplot analyses were carried out using JMP software, version
6.0.3 (SAS Institute Inc., Cary, NC). Multiple discriminant
analyses were performed in the discovery set, then validated in
the validation set with MATLAB software, version 7.6.0 (Math-
works, Natick, MA). Model performances were assessed using the
area under the ROC curve (ROC AUC) as a measure of the
validity of the MIAI. Details are given in Methods S1.
Results
Plasma His and Trp concentrations in IBD patients
Analysis of serum protein levels showed that serum albumin, but
not total protein level, was decreased in IBD patients. Interest-
ingly, the concentrations of several plasma AAs (e.g. histidine (His)
and tryptophan (Trp)) were significantly decreased, while the levels
of others were maintained in IBD patients (Table 2). Therefore,
the observed changes in the concentrations of plasma AAs
suggested that there is a metabolic alteration that occurs in
patients with IBD.
As shown in Figure 1A and Table 2, plasma His concentrations
were significantly decreased in both CD and UC patients
compared with HCs (mean plasma His concentrations, 72.3 mM
in CD patients and 71.0 mM in UC patients vs. 83.3 mM in HCs,
p,0.001). Furthermore, the plasma His concentration showed
significant decreases in patients with active disease (Figure 1B).
Specifically, the mean plasma His concentration was 62.0 mMi n
CD patients with active disease (CDa) compared with 74.6 mMi n
CD patients in remission (CDr) (p,0.001). Similarly, the plasma
His concentration was 65.0 mM in UCa patients compared with
76.6 mM in UCr patients (p,0.001). The plasma His concentra-
tion showed an inverse correlation with the CDAI in CD patients
(Spearman’s rank correlation coefficient rs=20.386, p,0.001)
and the CAI in UC patients (rs=20.425, p,0.001) (Figure 1C).
Most importantly, the plasma His concentration showed a highly
inverse correlation with serum CRP levels in CD patients
(rs=20.460, p,0.001) (Figure 1D and Table 3). Plasma Trp
concentrations were also significantly decreased in IBD patients
and inversely correlated with disease activity and serum CRP level.
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metabolism in IBD patients
To analyze AA metabolomics in IBD patients, we measured 22
fasting plasma AA concentrations, then carried out multivariate-
correlation analyses of these in IBD patients (UC: blue; CD: red)
and HCs (green) (Figure S1). The scatter plots for two plasma AAs
showed various patterns, and we observed a general imbalance of
branched-chain AAs (BCAAs) in IBD patients (Figure S2A, B).
MIAI for clinical diagnosis of IBD
Although we found that AA metabolism is altered in IBD
patients, it is difficult to establish a biomarker for clinical use based
on these measurements. To overcome this, we tried to assess the
AA metabolic condition of individuals by multivariate discrimi-
nant analysis of the plasma aminogram in the discovery set. The
MIAI established from the plasma aminograms discriminated
CD and UC patients from HCs with high specificity and sensitivity
in the discovery set: (Index (CD/HC)=22.435+5.1846[Tau]
22.6786[His]24.5206[Tyr]28.1656[Val]+7.2106[Ile], ROC
AUC=0.955; Index (UC/HC)=27.42227.59886[His]+4.6216
[Tau]22.1076[Tyr]24.9646[Asn]+2.9306[Thr], ROC AUC=
0.912) (Figure 2A and Table S1). These were then validated in
additional IBD patients (ROC AUC of 0.940 for Index (CD/HC)
and of 0.894 for Index (UC/HC), respectively) (Figure 2A).
Importantly, the AA components between Index (CD/HC) and
Index (UC/HC) differed, suggesting that AA metabolism differs
between the two diseases. Therefore, the MIAI may reflect not
Table 1. Patient characteristics.
CD UC HC
Discovery Set N 102 102 102
Age, years 36.169.9 35.969.4 36.468.6
Female, n (%) 32 (31) 32 (31) 32 (31)
Mean disease duration, years 11.067.4 7.866.7 –
Mean age at diagnosis, years 25.167.7 28.168.5 –
Active disease 29 38 –
CD characteristics
Disease location
Small bowel 31 – –
Colon 9 – –
Both 59 – –
Others 3 – –
Behavior (Montreal classification)
B1: non-stricturing, non-penetrating 26 – –
B2: stricturing 42 – –
B3: penetrating 34 – –
p: perianal disease modifier 40 – –
UC characteristics
Disease location
Proctitis – 12 –
Left sided colitis – 43 –
Entire colitis – 47 –
Treatment
Enteral nutrition 44 1 –
Steroids 12 37 –
Salicylates 91 98 –
Immunosuppressors 56 25 –
Infliximab 14 0 –
Biomarker levels Median (interquartile range)
Albumin (mg/dl) 4.2 (3.8–4.4) 4.5 (4.1–4.6) 4.6 (4.4–4.8)
C-reactive Protein (mg/dl) 0.22 (0.03–0.77) 0.19 (0.03–0.25) 0.02 (0.01–0.04)
Hemoglobin (g/dl) 12.8 (11.5–13.9) 13.9 (13.3–14.8) 15.2 (13.6–15.7)
Validation Set n 63 120 108
Age, years 32.3611.2 42.6616.2 42.467.9
Female, n (%) 20 (33) 40 (33) 34 (32)
Plus-minus values are means6standard deviation.
doi:10.1371/journal.pone.0031131.t001
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metabolism of IBD patients.
According to these observations, we hypothesized that the MIAI
is also useful for discrimination between CD and UC patients. As
shown inFigure 2B, the MIAI could discriminate between CDaand
UCa patients (Index (CDa/UCa)=215.134+5.2516[Ile]+2.6186
[Thr]+2.6346[Tau]25.1256[Trp]22.4856[Ar], ROC AUC=
0.879). By contrast, the MIAI showed less sensitivity and specificity
for discrimination between CDr and UCr patients (Index (CDr/
UCr)=8.09722.4436[Tyr]+2.3276[Gly]22.6336[Val]+3.2676
[Ile]22.1746[Ser], ROC AUC=0.744) (Figure 2B). These results
indicate that the differences in metabolic conditions between UC
and CDare more definedinactivediseases,suggestingthatan MIAI
based on plasma AA profiling has the potential for diagnostic use.
MIAI for assessing IBD disease activity
Next, we investigated the ability of the MIAI to assess disease
activity. The MIAI could discriminate between patients with active
disease and those in remission among both CD and UC patients
(CDa vs. CDr: Index (CDa/CDr)=16.47423.3426[His]2
5.1906[Trp]+1.8576[Tau]+2.7156[Met], ROC AUC=0.894;
UCa vs. UCr: Index (UCa/UCr)=34.01922.9266[Trp]2
1.8646[Tyr]24.7776[Val]22.8566[Met]+4.6046[Ile], ROC
AUC=0.849) (Figure 3A). As shown in Figure 3B, Index (CDa/
CDr) was unable to identify the activity of UC, indicating that this
index specifically identified the activity of CD. Furthermore, Index
(CDa/CDr) and Index (UCa/UCr) showed a positive correlation
with the CDAI (rs=0.592, p,0.001) and CAI (rs=0.598,
p,0.001), respectively (Figure 3C).
Table 2. Comparison of plasma amino acid (AA) concentrations in healthy control subjects, Crohn’s disease and ulcerative colitis
patients.
HC CD UC p
Albumin (g/dl) 4.660.2 4.160.5
2 4.360.5
2 ,0.001
1
Total Protein (g/dl) 7.260.3 7.360.7 7.460.5
2 ,0.001
1
EAA
Valine 219 (190–241) 195 (161–216)
4 191 (166–221)
4 ,0.001
3
Leucine 118 (98–135) 102 (84–119)
4 101 (85–117)
4 ,0.001
3
Isoleucine 61 (49–68) 57 (51–65) 54 (44–63)
4 0.028
3
Threonine 121 (108–134) 117 (97–146) 110 (94–130)
4 0.036
3
Lysine 192 (172–208) 187 (163–206) 174 (148–197)
4 0.005
3
Methionine 27 (24–29) 25 (21–29)
4 23 (20–26)
4 ,0.001
3
Histidine 83 (77–89) 72 (66–79)
4 72 (66–81)
4 ,0.001
3
Tryptophan 49 (42–56) 45 (38–52)
4 48 (40–55) 0.05
3
Phenylalanine 58 (51–63) 52 (46–61)
4 54 (47–58)
4 ,0.001
3
NEAA
Glutamic acid 32 (25–42) 39 (30–51) 39 (29–50) ,0.001
3
Asparagine 46 (41–51) 41 (37–48)
4 40 (35–46)
4 ,0.001
3
Serine 114 (98–129) 107 (97–122) 110 (85–124) 0.137
3
Glutamine 565 (525–613) 544 (494–592) 550 (474–590)
4 0.019
3
Glycine 231 (205–264) 241 (205–286) 218 (185–251)
4 0.002
3
Proline 122 (105–144) 145 (114–181)
4 125 (102–166) 0.001
3
Tyrosine 61 (55–68) 52 (44–60)
4 53 (46–60)
4 ,0.001
3
Arginine 91 (78–103) 89 (74–104) 87 (72–96) 0.254
3
Alanine 319 (265–362) 322 (261–379) 308 (271–356) 0.887
3
Other
Citrulline 31 (26–35) 28 (23–35) 28 (23–32)
4 0.003
3
Taurine 49 (44–56) 73 (58–99)
4 68 (53–86)
4 ,0.001
3
Ornithine 57 (51–68) 57 (48–67) 50 (44–58)
4 ,0.001
3
Sum of EAAs 932 (845–1019) 856 (761–963)
4 830 (745–915)
4 ,0.001
3
Sum of NEAAs 1615 (1490–1714) 1463 (1104–1713)
4 1562 (1395–1688) 0.002
3
EAA/NEAA 0.58 (0.54–0.63) 0.58 (0.52–0.71) 0.55 (0.50–0.58)
4 ,0.001
3
Serum albumine and total protein concentration are presented as mean6standard deviation. Plasma amino acid concentrations are presented as median (interquartile
range).
1One-way analysis of variance test.
2Significantly different from control subjects, p,0.01 (by Dunnett’s test).
3Kruskal Wallis Test.
4Significantly different from control subjects, p,0.01 (by Kruskal-Wallis after adjustment for CD and UC vs. HC by Dunn’s test).
doi:10.1371/journal.pone.0031131.t002
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Among the biggest expectations for clinical markers are their
ability to objectively monitor disease activity, their use in clinical
management issues,suchaswhento startinductiontherapyand how
long to continue maintenance therapy, and their ability to predict
prognosis, including the risk of surgery. Regarding these issues, we
continuously monitored Index (CDa/CDr) and Index (UCa/UCr)
to prospectively assess disease activity in several CDa and UCa
patients.AsshowninFigure 4,theMIAIswerereduced byinduction
therapy and correlated with clinical activity. These data suggest that
the MIAI may have potential as a clinical marker that can monitor
disease activity in individual patients for continued observation.
Discussion
In the present study, we have established the potential of the
MIAI for clinical use based on our analyses of the plasma
concentrations of 22 AAs and their metabolites in IBD patients.
Initially, we compared plasma aminograms of IBD patients with
those of HCs and observed several differences, which may reflect
nutritional condition, inflammation, and disease specific patho-
genesis. In particular, the aminograms indicated that plasma His
and Trp were significantly decreased in IBD patients with active
disease. Furthermore, plasma His and Trp concentrations showed
inverse correlations with disease activity indexes and serum CRP
levels. These observations suggest that the decreased plasma His
and Trp in IBD patients may reflect the chronic inflammatory
condition, and that supplementation with His and Trp may be a
novel therapeutic strategy for IBD. Trp is metabolized into
kynurenine by the catabolic enzyme, indoleamine 2,3-dioxygenase
(IDO), and Trp metabolism has recently been highlighted as an
immunological regulator [13,14,15]. It is also reported that plasma
kynurenine concentrations and IDO transcription levels are
altered in inflamed tissue of IBD patients [16,17].
Consistent with our observations, plasma His concentrations are
decreased in several chronic inflammatory disorders such as
rheumatoid arthritis and chronic kidney disease [18,19], and are
inversely correlated with the erythrocyte segmentation ratio (ESR)
in rheumatoid arthritis patients [18]. In a clinical trial of
rheumatoid arthritis patients, supplementation of 4.5 g L-His for
30 days showed clinical benefits in patients with more active and
prolonged disease [20]. In chronic kidney disease, plasma His
concentrations are inversely correlated with CRP and hepatocyte
growth factor, markers that reflect inflammation [19]. Further-
more, enteral nutrition therapy using an elemental diet, with a His
density more than twice that of the recommended WHO/FAO/
UN requirement, has shown efficacy in CD [21]. Importantly, we
previously reported that orally administered His ameliorates
intestinal inflammation in an IL-10-deficient transfer mouse colitis
model by inhibiting the production of pro-inflammatory cytokines
by activated macrophages through intracellular mechanisms [22].
Plasma AA profiles are affected by the levels of protein and AA
intake. Although the effects of the final meal on fasting
concentrations of plasma AA are minimal, animal studies have
shown that chronic alteration of protein intake affects fasting
concentrations [10]. Therefore, the observed aminogram changes
in IBD patients in the present study could be partially attributed to
changes in dietary intake. Indeed, it has been reported that up to
85% of patients hospitalized with exacerbations of IBD have
protein-energy malnutrition [23].
To date, several clinical markers that could aid the diagnosis of
IBD and monitor disease activity have been reported. These
include serological markers such as anti-neutrophil cytoplasmic
antibodies (ANCAs) for UC and anti-Saccharomyces cerevisiae
antibodies (ASCAs) for CD [24,25,26], although their practicality
for clinical use remains controversial because of their inconve-
nience. Moreover, they do not reflect disease activity, so have
limited use in monitoring the clinical course and therapeutic
efficacy. Alternative candidate clinical markers capable of
detecting inflammation and monitoring disease activity are fecal
markers and serum CRP.
Fecal markers such as calprotectin have been shown to
discriminate between active and inactive IBD, as well as non-
Table 3. Spearman’s rank correlation coefficients (rs) for
plasma amino acid concentrations.
CRP
CD (102) UC (95)
rs pr s p
Histidine 20.46 ,0.0001 20.29 0.0041
Tryptophan 20.37 0.0001 20.27 0.0093
Valine 20.08 NS 20.06 NS
Leucine 0.02 NS 20.02 NS
Isoleucine 20.07 NS 20.02 NS
Methionine 20.25 0.0112 20.08 NS
Phenylalanine 0.01 NS 0.05 NS
Threonine 20.08 NS 20.34 0.0007
Lysine 20.17 NS 20.01 NS
Tyrosine 0.11 NS 20.08 NS
Serine 20.03 NS 20.17 NS
Asparagine 20.24 0.0161 20.25 0.0163
Glutamic Acid 0.29 0.0028 0.15 NS
Glutamine 20.13 NS 20.13 NS
Proline 20.04 NS 20.19 NS
Glycine 20.07 NS 20.22 0.0353
Alanine 20.21 0.0327 20.14 NS
Cystine 0.06 NS 0.05 NS
Arginine 20.01 NS 20.13 NS
Ornithine 0.11 NS 0.04 NS
Citrulline 20.11 NS 20.08 NS
Taurine 0.08 NS 20.15 NS
NS, not significant.
doi:10.1371/journal.pone.0031131.t003
Figure 1. Plasma His and Trp concentrations in IBD patients. (A) Plasma His concentrations are significantly lower in CD (grey bars) and UC
(striped bars) patients than in HCs (white bars). Plasma Trp concentrations are significantly lower in CD patients than in HCs. The two-tailed p-values
are based on the Mann-Whitney U test with the Bonferroni correction. (B) Plasma His and Trp concentrations are significantly lower in patients with
active disease (CDa, dark grey bars, and UCa, dark striped bars) than in patients in remission (CDr, light grey bars, and UCr, light striped bars),
respectively. The two-tailed p-values are based on the Mann-Whitney U test. (C) Significant inverse correlations between plasma His and Trp
concentrations and disease activities (CDAI for CD and CAI for UC). (D) Significant inverse correlations between plasma His and Trp concentrations
and serum CRP concentrations in CD patients. The relationships in panels C and D are shown along with their Spearman’s rank correlation coefficients
(rs). Error bars show standard deviations.
doi:10.1371/journal.pone.0031131.g001
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PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e31131Figure 2. MIAI for clinical diagnosis of IBD. (A) ROCs of the MIAI for discriminating CD patients from HCs (Index (CD/
HC)=22.435+5.1846[Tau]22.6786[His]24.5206[Tyr]28.1656[Val]+7.2106[Ile]) and UC patients from HCs (Index (UC/HC)=
27.42227.59886[His]+4.6216[Tau]22.1076[Tyr]24.9646[Asn]+2.9306[Thr]). (B) ROCs of the MIAI for discriminating CD and UC patients in discovery
set (Index (CDa/UCa)=215.134+5.2516[Ile]+2.6186[Thr]+2.6346[Tau]25.1256[Trp]22.4856[Arg], ROC AUC=0.879; Index (CDr/UCr)=
8.09722.4436[Tyr]+2.3276[Gly]22.6336[Val]+3.2676[Ile]22.1746[Ser], ROC AUC=0.744). CDa, active CD; CDr, remission CD; UCa, active UC; UCr,
remission UC.
doi:10.1371/journal.pone.0031131.g002
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PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e31131IBD, based on intestinal inflammation [27]. However, although
fecal markers may have a high sensitivity, their disease specificity is
uncertain. Serum CRP is another non-invasive biomarker used to
detect inflammation and monitor disease activity, especially in CD
[27,28], but its diagnostic accuracy remains controversial. By
contrast, the MIAI is a convenient, non-invasive marker that may
reflect disease activity more sensitively and specifically than other
reported markers. Although the cost of plasma AA profiling in
practical use is relatively more expensive than that of fecal
calprotectin or serum CRP at present, we believe that it is possible
to reduce the cost for testing plasma AA profiles by targeting
several promising AAs and developing a novel enzymatic detection
system of each AA as has been already achieved measurement of a
BCAAs/tyrosine ratio (BTR). Since the MIAI integrates disease-
specific alterations of AA metabolism, it can reflect individual
conditions more objectively than analyses by solo factors (such as
His). Although further investigations including prospective obser-
vations are required, the MIAI appears to be a promising marker
that enables us to predict disease prognosis and manage patients
accordingly.
In conclusion, the MIAI based on statistical modeling of plasma
aminograms is a novel, non-invasive, objective parameter for the
diagnosis and assessment of disease activity in IBD patients. It was
shown to be capable of significantly discriminating between HCs
and CD or UC patients with very high sensitivity and specificity, as
well as between CD and UC patients, and those with active disease
or undergoing remission. The introduction of metabolomics into
IBD clinics has provided us with new insights and will contribute
to the establishment of clinical parameters and our understanding
of IBD pathophysiology.
Supporting Information
Figure S1 Scatter plots of plasma AA concentrations in
individual HCs and IBD patients. Each panel represents the
scatterplot of two plasma AAs from individual HCs (green), CD
patients (red), and UC patients (blue). Panel shows correlation
plots of the concentrations of 22 AAs.
(TIF)
Figure S2 A general imbalance of branched-chain AAs
(BCAAs) in IBD patients. (A) Correlation plots of leucine (Leu),
valine (Val), and isoleucine (Ile). Ellipses show that 95% of the
values are in a bivariate normal distribution. (B) Mean plasma
Leu, Ile, and Val concentrations in active CD (CDa), remission
CD (CDr), active UC (UCa), and remission UC (UCr) patients.
Error bars show standard deviations. The two-tailed p-values are
based on the Mann-Whitney U test.
(TIF)
Table S1 Candidates of MIAI for clinical diagnosis of
IBD.
(DOC)
Methods S1 Statistical analysis.
(DOC)
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